Skip to main content
Premium Trial:

Request an Annual Quote

People in the News

Akoya Biosciences: Myla Lai-Goldman

Akoya Biosciences has appointed Myla Lai-Goldman to its board of directors. From 1990 to 2008, Lai-Goldman held various roles at Laboratory Corporation of America and its predecessor company, Roche Biomedical Laboratories, including executive vice president, chief medical officer, and chief scientific officer. She is currently the chair of precision medicine company GeneCentric Therapeutics, which she cofounded and for which she previously served as CEO and president. She is also a venture partner with Hatteras Venture Partners and managing partner of Personalized Science, a diagnostic consulting company that she founded in 2008. She is board certified in anatomic and clinical pathology, and received her medical degree from Columbia University College of Physicians and Surgeons.

MiRxes: David Capes

MiRxes, a developer of RNA-based test for early disease detection, has appointed David Capes as senior vice president and global head of innovation. Capes most recently served as VP of R&D for Greater Asia at Becton Dickinson. Prior to this, he held senior management roles at Pathway Biomed and Rockeby Biomed. He holds a PhD in pharmacy from Curtin University.

IsoPlexis: Jason Myers

IsoPlexis has appointed biochemist and biotechnology innovator Jason Myersto its board of directors. Myers is the CEO of GenapSys. He was previously a board member of Invitae, and was cofounder, CEO, and a director of ArcherDx from 2015 to 2020. 

Dotmatics: Mike McKee

Dotmatics has hired Mike McKee as president, replacing company founder Stephen Gallagher, whom the firm said would continue to manage strategic growth investments, acquisitions, and product expansion opportunities. McKee previously was executive VP and GM of insider threat at cybersecurity firm Proofpoint. Before that, he was CEO of ObserveIT, a startup that Proofpoint acquired in 2019. Dotmatics itself was acquired by Insightful Science this year, and McKee will lead technology integration efforts stemming from that deal. 

Foundation Medicine: Mia Levy

Roche subsidiary Foundation Medicine announced it has appointed medical oncologist Mia Levy as CMO. Levy specializes in breast cancer treatment and biomedical informatics and previously served as director of the Cancer Center at Rush University Medical Center. She led the development of My Cancer Genome, an international resource for clinicians and patients to get information about cancer-driving mutations, clinical trials, and therapies. 

Levy has also served as an associate professor of cancer research, biomedical informatics, and medicine at Vanderbilt University, as well as the director of clinical cancer informatics for the Vanderbilt-Ingram Cancer Center.

She is a member of the National Cancer Policy Forum for the National Academies and a member of the National Cancer Institute Clinical Trials and Translational Research Advisory Committee.

CareDx: Art Torres

CareDx has appointed patient advocate, political leader, and former state senator Art Torres to its board of directors.

Torres began his career by working alongside Cesar Chavez for the rights of farm workers in California. He later served for 20 years in the California legislature, chairing the State Assembly’s Health Committee, and then was elected as chair of the State Democratic Party. He is also a colon cancer survivor.

Currently, Torres serves as vice chair of the governing board of the California Institute for Regenerative Medicine, as well as a member of the University of California Board of Regents and the Covered California board overseeing the Affordable Care Act. He is also the vice chair on the board of One Legacy, an organ transplant foundation based in Southern California.

Ancestry: Brian Donnelly, Ashish Nayyar, Heather Friedland

Ancestry has appointed Brian Donnelly as senior VP and general manager of AncestryDNA and Ashish Nayyar as chief data officer, and has promoted Heather Friedland to chief product officer.

Donnelly joins the firm from Amazon, where he was head of diagnostics and genomics. Prior to that, he held various roles at genomics companies including Sequenom and Illumina, and was chief commercial officer at Codex DNA.

Nayyar comes to Ancestry from Facebook, where he was senior director of data science.

Friedland was most recently Ancestry's senior VP of new products and growth. Previously, she served as chief product officer at Glassdoor.

Sera Prognostics: Michael Foley

Sera Prognostics has appointed Michael Foley its CMO, starting in January 2022. He is currently chairman of obstetrics and gynecology at the University of Arizona College of Medicine Phoenix/Banner good Samaritan Regional Medical Center, from which he will retire on Dec. 31, 2021. He is also the lead editor of Obstetric Intensive Care: A Practical Manual.

PhRMA Foundation: Amy Miller

Amy Miller is the new president at PhRMA Foundation, an organization that invests in healthcare research. Miller takes over the role from Eileen Cannon, who decided to retire after 22 years at the foundation's helm. Previously, Miller was president and CEO of the Society for Women's Health Research and executive VP of the Personalized Medicine Coaltion, where she spearheaded efforts to increase adoption and funding for diagnostics and personalized treatment strategies. According to a statement from PhRMA Foundation, its board of directors unanimously selected Miller as the organization's new president based on her "demonstrated success in nonprofit leadership" and her track record as a "trusted leader and consensus builder among health stakeholders, particularly in precision medicine regulatory issues and in health outcomes and value assessment research."

Tesis Labs: Jonathan Stein

Jonathan Stein has been named as the first CSO and medical director of Tesis Labs, a genetic testing company based in Phoenix, Arizona. Previously, he was CSO at Spectracell Laboratories after serving as the company's lab director. Before that, he was medical director and clinical consultant at Apex Molecular Laboratories, associated DNA lab director at Identigene, and a research investigator at the University of Texas MD Anderson Cancer Center. Stein holds a PhD in molecular and cancer genetics and a master's degree in population and biomedical sciences from the University of Texas Health Science Center as well as a bachelor's degree in biochemistry from the University of California, Santa Cruz.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.